Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder
Shares of Fortinet, Inc. (NASDAQ: FTNT) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued guidance.
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering.
Panbela Therapeutics shares dipped 65.5% to $1.47 on Monday.